Biofrontera Inc. (BFRI)
Biofrontera Statistics
Share Statistics
Biofrontera has 9.21M shares outstanding. The number of shares has increased by 74.36% in one year.
| Shares Outstanding | 9.21M |
| Shares Change (YoY) | 74.36% |
| Shares Change (QoQ) | 14.51% |
| Owned by Institutions (%) | 0.74% |
| Shares Floating | 7.61M |
| Failed to Deliver (FTD) Shares | 757 |
| FTD / Avg. Volume | 0.68% |
Short Selling Information
The latest short interest is 52.88K, so 0.6% of the outstanding shares have been sold short.
| Short Interest | 52.88K |
| Short % of Shares Out | 0.6% |
| Short % of Float | 0.6% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -0.34 and the forward PE ratio is -3.33. Biofrontera's PEG ratio is 0.
| PE Ratio | -0.34 |
| Forward PE | -3.33 |
| PS Ratio | 0.16 |
| Forward PS | 0.1 |
| PB Ratio | 1.36 |
| P/FCF Ratio | -0.58 |
| PEG Ratio | 0 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Biofrontera.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.72, with a Debt / Equity ratio of 1.11.
| Current Ratio | 1.72 |
| Quick Ratio | 1.17 |
| Debt / Equity | 1.11 |
| Debt / EBITDA | -0.34 |
| Debt / FCF | -0.48 |
| Interest Coverage | -8.17 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $405.47K |
| Profits Per Employee | $-193.03K |
| Employee Count | 92 |
| Asset Turnover | 1.69 |
| Inventory Turnover | 2.8 |
Taxes
| Income Tax | 22K |
| Effective Tax Rate | -0.12% |
Stock Price Statistics
The stock price has increased by -64.29% in the last 52 weeks. The beta is 0.37, so Biofrontera's price volatility has been higher than the market average.
| Beta | 0.37 |
| 52-Week Price Change | -64.29% |
| 50-Day Moving Average | 0.88 |
| 200-Day Moving Average | 1.02 |
| Relative Strength Index (RSI) | 37.65 |
| Average Volume (20 Days) | 111.16K |
Income Statement
In the last 12 months, Biofrontera had revenue of 37.3M and earned -17.76M in profits. Earnings per share was 0.
| Revenue | 37.3M |
| Gross Profit | 18.7M |
| Operating Income | -17.21M |
| Net Income | -17.76M |
| EBITDA | -14.44M |
| EBIT | -15.63M |
| Earnings Per Share (EPS) | 0 |
Balance Sheet
The company has 5.91M in cash and 4.92M in debt, giving a net cash position of 983K.
| Cash & Cash Equivalents | 5.91M |
| Total Debt | 4.92M |
| Net Cash | 983K |
| Retained Earnings | -117.41M |
| Total Assets | 22.1M |
| Working Capital | 8.68M |
Cash Flow
In the last 12 months, operating cash flow was -10.27M and capital expenditures -10K, giving a free cash flow of -10.28M.
| Operating Cash Flow | -10.27M |
| Capital Expenditures | -10K |
| Free Cash Flow | -10.28M |
| FCF Per Share | -1.86 |
Margins
Gross margin is 50.12%, with operating and profit margins of -46.14% and -47.61%.
| Gross Margin | 50.12% |
| Operating Margin | -46.14% |
| Pretax Margin | -47.55% |
| Profit Margin | -47.61% |
| EBITDA Margin | -38.71% |
| EBIT Margin | -46.14% |
| FCF Margin | -27.56% |
Dividends & Yields
BFRI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for BFRI is $7, which is 900% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 900% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
Stock Splits
The last stock split was on Jul 5, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Jul 5, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -7.98 |
| Piotroski F-Score | 4 |